Opinions Cameron Hurst
Corbus Pharmaceuticals HoldingCRBP-OCOMMENTJul 11, 2018
N/A
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
A stage three pharmaceutical company on the smaller cap side. If it hits, it could go from $5 to $40. He prefers a basket approach to diversify risk. If they continue to miss earnings, and there is uncertainty over trade wars this could worsen.